Evidence map›Paper›PMID 42756419›Full record

ArticleFrontiers in immunology2026

Mechanisms of therapeutic antibodies immunogenicity: infliximab oligomeric aggregates increase T-cell response and uptake by dendritic cells involving mannose-sensitive receptor CD206.

Maria Lteif, Myriam Nabhan, Cécile Tardif, Claire Smadja, Jennifer Mata-Orozco, Stéphane Hua, Bernard Maillère, Marc Pallardy, Isabelle Turbica

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Maria LteifUniversité Paris Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM), Inflammation, Microbiome, Immunosurveillance, Faculté de Pharmacie, Orsay, France.
Myriam NabhanUniversité Paris Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM), Inflammation, Microbiome, Immunosurveillance, Faculté de Pharmacie, Orsay, France.
Cécile TardifUniversité Paris Saclay, Centre National de la Recherche Scientifique (CNRS) UMR 8612, Institut Galien Paris Saclay, Orsay, France.
Claire SmadjaUniversité Paris Saclay, Centre National de la Recherche Scientifique (CNRS) UMR 8612, Institut Galien Paris Saclay, Orsay, France.
Jennifer Mata-OrozcoUniversité Paris-Saclay, Commissariat à l'énergie Atomique (CEA), Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement (INRAE), Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
Stéphane HuaUniversité Paris-Saclay, Commissariat à l'énergie Atomique (CEA), Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement (INRAE), Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
Bernard MaillèreUniversité Paris-Saclay, Commissariat à l'énergie Atomique (CEA), Institut National de Recherche pour l'Agriculture, l'alimentation et l'Environnement (INRAE), Département Médicaments et Technologies pour la Santé, SIMoS, Gif-sur-Yvette, France.
Marc PallardyUniversité Paris Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM), Inflammation, Microbiome, Immunosurveillance, Faculté de Pharmacie, Orsay, France.
Isabelle TurbicaUniversité Paris Saclay, Institut National de la Santé et de la Recherche Médicale (INSERM), Inflammation, Microbiome, Immunosurveillance, Faculté de Pharmacie, Orsay, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Aggregation of therapeutic antibodies (Ab)s is now recognized as a major product-related factor associated with increased potential of immunogenicity. Regulatory agencies have established limits for the presence of (sub)visible particles in commercialized products. These particles are considered a potential risk factor for the development of unwanted immune responses. However, little is known concerning the role of oligomeric Abs aggregates of nanometric size in Abs' immunogenicity. The objective of this work was to better understand the role and the mechanisms of T-cell response to nanometric Ab aggregates using infliximab (IFX) as a model. Method: We produced nanosized IFX aggregates by exposing native IFX to ultraviolet light. These aggregates were characterized using size exclusion chromatography (SEC), dynamic light scattering (DLS) and field flow fractionation coupled with a multi-angle light scattering detector (FFF-MALS). We then investigated the impact of IFX aggregation on its uptake by dendritic cells and the subsequent activation of IFX-specific T-cell responses. Results: Using a human in vitro autologous dendritic cell (DC)/T-cells coculture assay, we showed that aggregation increased the frequency of responsive T cells to IFX. Moreover, we observed exclusive T-cell responses to IFX aggregates and different TCR clonotypes responding to each form of IFX. Using fluorescent native or aggregated IFX, we found a significantly higher internalization rate of aggregated IFX by DCs in a mannose-dependent manner. Confocal microscopy experiments showed that aggregates were rapidly internalized and associated with markers of early endosomes and lysosomes as well as antigen presentation molecules, compared to the native form of IFX. Discussion: Our results suggest that internalization of IFX oligomeric aggregates via the mannose receptor pathway significantly contributes to enhanced IFX uptake by DCs and increased routing into the degradative pathway for processing into peptides. Increased presentation of immunogenic peptides may contribute to the augmentation of T-cell recruitment with aggregates compared to the native form. .

Indexed as

Dendritic CellsInfliximabLectins, C-TypeMannose-Binding LectinsReceptors, Cell SurfaceT-LymphocytesHumansLymphocyte ActivationMannose ReceptorProtein AggregatesInfliximabLectins, C-TypeMannose-Binding LectinsMannose ReceptorProtein AggregatesReceptors, Cell Surfaceaggregationdendritic cellsimmunogenicityinternalizationT cell repertoire

Identifiers

PMID42756419
PMCPMC13582642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.